The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...

Sarepta ( SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

Bausch Health is buying late-stage biopharmaceutical company Durect for about $63 million in cash up front, plus two possible additional payments totaling up to $350 million.

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term ...

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

Alfasigma is in discussions with the EMA and MHRA about Jyseleca for axSpA but has yet to reveal any plans for US submission.

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alc ...